Ribupatide Oral (KAI-9531-T) (GLP-1/GIP Agonist)

May 26, 2026 — Kailera Therapeutics, Inc. (Nasdaq: KLRA) reported Q1 2026 financial results (quarter ended March 31, 2026) and provided clinical/program updates for its obesity pipeline, including partnered programs with Hengrui in China. The company initiated five late-stage global obesity trials, highlighted by the Phase 3 KaiNETIC program for once-weekly ribupatide injection (KAI-9531) (three placebo-controlled trials up to 10 mg over 76 weeks; data anticipated in 2028) and a U.S. Phase 2b high-dose trial (up to 20 mg over 48 weeks; ~250 participants; data anticipated in 2027). Positive topline Phase 2 China data for ribupatide oral showed up to 12.1% mean weight loss at Week 26 (no plateau) and 38.6% achieving ≥15% weight loss, with low GI adverse event rates; Phase 3 global trials may start as early as 1H 2027 pending regulators. For KAI-7535 (oral GLP-1 RA), Hengrui’s Phase 3 T2D OUTSTAND-1 met its primary endpoint with HbA1c reductions of 1.40%–1.68% vs 0.06% placebo and no liver safety signal; an NDA submission in China is planned. For KAI-4729 (injectable tri-agonist), Hengrui Phase 1 MAD reported up to 16.0% mean weight loss at Week 12 (12 mg) vs 5.4% placebo, supporting Phase 2 plans in China and a ex-China Phase 1 in 2026.

Financially, Kailera reported cash/cash equivalents/marketable securities of $581.9M as of March 31, 2026; with $718.8M gross IPO proceeds (44.9M shares at $16; IPO April 17, 2026), management expects funding into mid-2028. Q1 2026 R&D expense was $70.9M (vs $10.1M in Q1 2025), G&A was $13.8M (vs $10.3M), and net loss was $78.9M (vs $18.0M), reflecting accelerated clinical development.